<p>Vigonvita Life Sciences Co. Ltd. announced that it has entered into a license agreement with Simcere Pharmaceutical Group Limited. Under the agreement, Simcere Pharmaceutical will receive exclusive license rights for Vigonvita’s drug candidate, deuremidevir hydrobromide (VV116), in the Greater China region for new indications, specifically for the treatment of infections caused by respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251203-11941195), on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

02096

<p>Vigonvita Life Sciences Co. Ltd. has signed a license agreement with Simcere Pharmaceutical Group Limited. Simcere will receive exclusive rights for Vigonvita's drug candidate, deuremidevir hydrobromide (VV116), in Greater China for new indications, specifically for treating infections caused by RSV and HMPV.</p>

Vigonvita Life Sciences Signs License Agreement With Simcere Pharmaceutical for VV116 New Indications